Released Mar 18, 2021, before the open
10-K filed Mar 18, 2021, 77 days after period end · 0001193125-21-085777
Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$251.00K$251.00K derivedno prior Q4 2019 on file+40.2% vs Q3 2020
Net Income-$20.76M-$20.76M derivedno prior Q4 2019 on fileN/M vs Q3 2020
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$20,779,000—
Operating Cash Flowderived-$10,655,000N/M
Free Cash Flowderived-$18,144,000N/M
Margins · derived
Operating margin-8278.5%
Net margin-8270.1%
What the release said
The release
Same quarter
| Metric | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures |
|---|---|---|
| Revenue | $251.00K | — |
| Net Income | -$20.76M | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR